Ozempic and GLP-1 Drugs
Ozempic and other GLP-1 receptor agonists have swept the world for obesity and type 2 diabetes. Their extended value is reducing inflammation and improving clinical outcomes in heart disease by 20% or more. Kidney diseases along with promising but less consistent evidence in liver diseases, while research in autoimmune diseases and dementia remains preliminary.




















